Treatment of Multiple Myeloma: Insights From Experts at The Ohio State University

home / around-the-practice / treatment-of-multiple-myeloma-insights-from-experts-at-the-ohio-state-university

A panel of experts from The Ohio State University discuss key data updates in multiple myeloma from recent meetings and how it applies to improving patient outcomes in clinical practice.

Personalized Therapy Options Are on the Horizon in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com.

EP. 1: Personalized Therapy Options Are on the Horizon in Multiple Myeloma

Ariana Pelosci
May 20th 2023

Ashley E. Rosko, MD, reviews unmet needs and treatment sequencing for patients with multiple myeloma.

Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)

EP. 2: Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
May 25th 2023

Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.

Transplant Eligibility in Patients With NDMM

EP. 3: Transplant Eligibility in Patients With NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
May 25th 2023

Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.

Treatment Considerations for Patients with High-Risk NDMM

EP. 4: Treatment Considerations for Patients with High-Risk NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 1st 2023

Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.

First-Line Treatment Options for Patients With Transplant-Ineligible NDMM

EP. 5: First-Line Treatment Options for Patients With Transplant-Ineligible NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 1st 2023

Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.

Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial

EP. 6: Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 8th 2023

Naresh Bumma, MD, reviews updated data from the MAIA trial in transplant-ineligible newly-diagnosed multiple myeloma.

Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM

EP. 7: Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 8th 2023

April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.

Available Treatment Options for Patients with Relapsed Multiple Myeloma

EP. 8: Available Treatment Options for Patients with Relapsed Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 15th 2023

Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.

Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma

EP. 9: Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 15th 2023

Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.

Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma

EP. 10: Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 22nd 2023

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma

EP. 11: CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 22nd 2023

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

EP. 12: Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C
June 22nd 2023

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.